Medulloblastoma (MB) comprises a biologically heterogeneous group of embryonal tumours
of the cerebellum. Four subgroups of MB have been described (WNT, sonic hedgehog …

Current therapies for medulloblastoma were introduced primarily in the 1980s and consist of
predominantly cytotoxic, nontargeted approaches. Mortality from medulloblastoma remains …

How abnormal neurodevelopment relates to the tumour aggressiveness of medulloblastoma
(MB), the most common type of embryonal tumour, remains elusive. Here we uncover a …

There is a pressing need to identify therapeutic targets in tumors with low mutation rates
such as the malignant pediatric brain tumor medulloblastoma. To address this challenge, we …

Obtaining accurate drug response data in large cohorts of cancer patients is very
challenging; thus, most cancer pharmacogenomics discovery is conducted in preclinical …

Medulloblastoma is among the most common malignant brain tumors in children. Recent
studies have identified at least four subgroups of the disease that differ in terms of molecular …

Medulloblastoma is a malignant tumor of the cerebellum and the most frequent malignant
brain tumor in children. The standard of care consists of maximal resection surgery, followed …

Purpose: Bioinformatics analysis followed by in vivo studies in patient-derived xenograft
(PDX) models were used to identify and validate CDK 4/6 inhibition as an effective …

Brain tumors are the leading cause of cancer-related death in children, and
medulloblastoma (MB) is the most common malignant pediatric brain tumor. Advances in …

Recent advances in cancer genomics have revealed 4 distinct subgroups of
medulloblastomas, each with unique transcription profiles, DNA alterations and clinical …